RATIONALE: Pulmonary arterial hypertension (PAH) is a progressive and fatal disease characterized by pulmonary arterial muscularization due to excessive pulmonary vascular cell proliferation and migration, a phenotype dependent upon growth factors and activation of receptor tyrosine kinases (RTKs). p130(Cas) is an adaptor protein involved in several cellular signaling pathways that control cell migration, proliferation, and survival. OBJECTIVES: We hypothesized that in experimental and human PAH p130(Cas) signaling is overactivated, thereby facilitating the intracellular transmission of signal induced by fibroblast growth factor (FGF)2, epidermal growth factor (EGF), and platelet-derived growth factor (PDGF). MEASUREMENTS AND MAIN RESULTS: In patients with PAH, levels of p130(Cas) protein and/or activity are higher in the serum, in the walls of distal pulmonary arteries, in cultured smooth muscle cells (PA-SMCs), and in pulmonary endothelial cells (P-ECs) than in control subjects. These abnormalities in the p130(Cas) signaling were also found in the chronically hypoxic mice and monocrotaline-injected rats as models of human PAH. We obtained evidence for the convergence and amplification of the growth-stimulating effect of the EGF-, FGF2-, and PDGF-signaling pathways via the p130(Cas) signaling pathway. We found that daily treatment with the EGF-R inhibitor gefitinib, the FGF-R inhibitor dovitinib, and the PDGF-R inhibitor imatinib started 2 weeks after a subcutaneous monocrotaline injection substantially attenuated the abnormal increase in p130(Cas) and ERK1/2 activation and regressed established pulmonary hypertension. CONCLUSIONS: Our findings demonstrate that p130(Cas) signaling plays a critical role in experimental and idiopathic PAH by modulating pulmonary vascular cell migration and proliferation and by acting as an amplifier of RTK downstream signals.
RATIONALE: Pulmonary arterial hypertension (PAH) is a progressive and fatal disease characterized by pulmonary arterial muscularization due to excessive pulmonary vascular cell proliferation and migration, a phenotype dependent upon growth factors and activation of receptor tyrosine kinases (RTKs). p130(Cas) is an adaptor protein involved in several cellular signaling pathways that control cell migration, proliferation, and survival. OBJECTIVES: We hypothesized that in experimental and human PAH p130(Cas) signaling is overactivated, thereby facilitating the intracellular transmission of signal induced by fibroblast growth factor (FGF)2, epidermal growth factor (EGF), and platelet-derived growth factor (PDGF). MEASUREMENTS AND MAIN RESULTS: In patients with PAH, levels of p130(Cas) protein and/or activity are higher in the serum, in the walls of distal pulmonary arteries, in cultured smooth muscle cells (PA-SMCs), and in pulmonary endothelial cells (P-ECs) than in control subjects. These abnormalities in the p130(Cas) signaling were also found in the chronically hypoxic mice and monocrotaline-injected rats as models of human PAH. We obtained evidence for the convergence and amplification of the growth-stimulating effect of the EGF-, FGF2-, and PDGF-signaling pathways via the p130(Cas) signaling pathway. We found that daily treatment with the EGF-R inhibitor gefitinib, the FGF-R inhibitor dovitinib, and the PDGF-R inhibitor imatinib started 2 weeks after a subcutaneous monocrotaline injection substantially attenuated the abnormal increase in p130(Cas) and ERK1/2 activation and regressed established pulmonary hypertension. CONCLUSIONS: Our findings demonstrate that p130(Cas) signaling plays a critical role in experimental and idiopathic PAH by modulating pulmonary vascular cell migration and proliferation and by acting as an amplifier of RTK downstream signals.
Authors: Yuliya Pylayeva; Kelly M Gillen; William Gerald; Hilary E Beggs; Louis F Reichardt; Filippo G Giancotti Journal: J Clin Invest Date: 2009-01-19 Impact factor: 14.808
Authors: Frédéric Perros; David Montani; Peter Dorfmüller; Ingrid Durand-Gasselin; Colas Tcherakian; Jérôme Le Pavec; Michel Mazmanian; Elie Fadel; Sacha Mussot; Olaf Mercier; Philippe Hervé; Dominique Emilie; Saadia Eddahibi; Gérald Simonneau; Rogério Souza; Marc Humbert Journal: Am J Respir Crit Care Med Date: 2008-04-17 Impact factor: 21.405
Authors: Lambert C J Dorssers; Ton van Agthoven; Arend Brinkman; Jos Veldscholte; Marcel Smid; Koen J Dechering Journal: Breast Cancer Res Date: 2004-11-16 Impact factor: 6.466
Authors: Sébastien Bonnet; Steeve Provencher; Christophe Guignabert; Frédéric Perros; Olivier Boucherat; Ralph Theo Schermuly; Paul M Hassoun; Marlene Rabinovitch; Mark R Nicolls; Marc Humbert Journal: Am J Respir Crit Care Med Date: 2017-03-01 Impact factor: 21.405
Authors: Kang Wu; Haiyang Tang; Ruizhu Lin; Shane G Carr; Ziyi Wang; Aleksandra Babicheva; Ramon J Ayon; Pritesh P Jain; Mingmei Xiong; Marisela Rodriguez; Shamin Rahimi; Francesca Balistrieri; Shayan Rahimi; Daniela Valdez-Jasso; Tatum S Simonson; Ankit A Desai; Joe G N Garcia; John Y-J Shyy; Patricia A Thistlethwaite; Jian Wang; Ayako Makino; Jason X-J Yuan Journal: Pulm Circ Date: 2020-09-10 Impact factor: 3.017
Authors: Edda Spiekerkoetter; Elena A Goncharova; Christophe Guignabert; Kurt Stenmark; Grazyna Kwapiszewska; Marlene Rabinovitch; Norbert Voelkel; Harm J Bogaard; Brian Graham; Soni S Pullamsetti; Wolfgang M Kuebler Journal: Pulm Circ Date: 2019-11-20 Impact factor: 3.017